Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Non-Current Assets (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Other Non-Current Assets for 5 consecutive years, with $715000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 14.04% year-over-year to $715000.0, compared with a TTM value of $715000.0 through Dec 2025, up 14.04%, and an annual FY2025 reading of $715000.0, up 14.04% over the prior year.
  • Other Non-Current Assets was $715000.0 for Q4 2025 at Aligos Therapeutics, roughly flat from $713000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.6 million in Q1 2022 and bottomed at $21000.0 in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $490350.0, with a median of $626000.0 recorded in 2023.
  • The sharpest move saw Other Non-Current Assets plummeted 89.12% in 2022, then soared 1402.38% in 2024.
  • Year by year, Other Non-Current Assets stood at $164000.0 in 2021, then surged by 286.59% to $634000.0 in 2022, then fell by 1.42% to $625000.0 in 2023, then increased by 0.32% to $627000.0 in 2024, then grew by 14.04% to $715000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for ALGS at $715000.0 in Q4 2025, $713000.0 in Q3 2025, and $640000.0 in Q2 2025.